Research & Development

KUSTE BIOPHARMA has been founded in 2019 with the aim to deliver new anti-inflammatory local treatment with first indication for Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC).

Know more

Pipeline

Our molecules have the potential to become the first approved JNK inhibitor treatment for BPS/IC directly treating inflammation.

cliquez pour agrandir

Our molecules

KUSTE BIOPHARMA owns two JNK inhibitors previously extensively studied, and whose safety and efficacy have been demonstrated in a variety of therapeutic applications.

Our molecules have a strong safety profile, they have proven effects in local delivery and can therefore be used by the urology practitioner to treat BPS/IC.

Research & Development